Data set from Nano G, Muzzarelli L, Malacrida G, Righini PC, Marrocco-Trischitta MM, Mazzaccaro D. Endovascular repair of thoracic and thoraco-abdominal aortic lesions. Ann Ital Chir. 2019;90:191-200. PMID: 31354152.

Data set from Nano G, Muzzarelli L, Malacrida G, Righini PC, Marrocco-Trischitta MM, Mazzaccaro D. Endovascular repair of thoracic and thoraco-abdominal aortic lesions. Ann Ital Chir. 2019;90:191-200. PMID: 31354152. This is the abstract: <strong>Background: </strong> We report our "real-world" experience of endovascular repair of thoracic/thoraco-abdominal aortic lesions in patients treated from May 2002 to May 2017. <strong>Methods: </strong> Data of all consecutive treated patients were retrospectively collected in a database and analyzed. Patients were divided into 4 groups: atherosclerotic thoracic/thoraco-abdominal aneurysms (TAA/TAAA) and floating thrombus (group A); acute complicated type B dissection (TBD), penetrating aortic ulcers (PAU) and intra-mural hematomas (IMH) in group B; chronic TBD evolving in TAA (group C); traumatic injuries (group D). Mortality, reinterventions and occurrence of neurological complications, both at 30 days and in the long term, were analyzed as primary outcomes for each group. <strong>Results: </strong> Ninety-four patients were treated complessively, most for a TAA (55.3%). Thirty-days deaths and neurological complications were observed in group A only (5 cases each, 5.3%). A reintervention was necessary in 6 patients (6.4%) of group A. At 5 years, in group A survival was 62.8%±6.3% and freedom from neurological complication was 88.3%±4.2%. Neither deaths nor neurological complications were recorded in the other groups. No late aortic ruptures were recorded. Freedom from reintervention in group A was 54.7%±7.6% at 5 years and a reintervention was needed in all patients of group D. Overall, the main cause for reintervention was a type I endoleak. <strong>Conclusions: </strong> The endovascular repair of thoracic/thoraco-abdominal aortic lesions had acceptable mortality and neurological complication rates, both at 30 days and in the long term. Reinterventions in the long term occurred more frequently after TAA/TAAA and traumatic injuries, and were mainly required for a type I endoleak.本数据集来源于Nano G、Muzzarelli L、Malacrida G、Righini PC、Marrocco-Trischitta MM、Mazzaccaro D的研究：《胸及胸腹主动脉病变的腔内修复术（endovascular repair of thoracic and thoraco-abdominal aortic lesions）》，发表于《意大利外科学年鉴（Ann Ital Chir）》2019年；90卷：191-200页，PMID：31354152。 <strong>背景：</strong> 本研究报告了2002年5月至2017年5月期间接受胸/胸腹主动脉病变腔内修复术患者的‘真实世界’诊疗经验。 <strong>方法：</strong> 回顾性收集所有连续收治的手术患者数据并录入数据库进行分析。将患者分为4组：A组为动脉粥样硬化性胸/胸腹主动脉瘤（atherosclerotic thoracic/thoraco-abdominal aneurysms, TAA/TAAA）合并漂浮血栓（floating thrombus）患者；B组为急性复杂性B型主动脉夹层（acute complicated type B dissection, TBD）、穿透性主动脉溃疡（penetrating aortic ulcers, PAU）及壁内血肿（intra-mural hematomas, IMH）患者；C组为进展为胸主动脉瘤的慢性B型主动脉夹层患者；D组为创伤性主动脉损伤患者。以各组的30天及长期死亡率、再干预率和神经系统并发症发生率作为主要结局指标进行分析。 <strong>结果：</strong> 共计纳入94例接受手术的患者，其中多数为胸主动脉瘤患者（55.3%）。仅A组出现30天死亡及神经系统并发症（各5例，占比5.3%）。A组中有6例患者（6.4%）需要接受再干预。术后5年时，A组生存率为62.8%±6.3%，无神经系统并发症比例为88.3%±4.2%。其余各组均未记录到死亡及神经系统并发症，亦未出现晚期主动脉破裂。A组术后5年无再干预比例为54.7%±7.6%，而D组所有患者均需接受再干预。总体而言，再干预的主要诱因为I型内漏（type I endoleak）。 <strong>结论：</strong> 胸及胸腹主动脉病变的腔内修复术在30天及长期随访中均表现出可接受的死亡率与神经系统并发症发生率。长期再干预在TAA/TAAA及创伤性主动脉损伤患者中更为常见，且主要由I型内漏导致。